Analysis of US Patent 9,186,392: Claims and Patent Landscape
US Patent 9,186,392 (issued November 17, 2015) discloses a composition and methods related to a specific therapeutic application. The patent's claims focus on a combination of active compounds designed for targeted treatment. This report evaluates the scope of the claims and maps the patent landscape in relevant fields.
Patent Claims Overview
The patent includes a total of 20 claims, with claims 1-10 being independent and asserting broad coverage over the composition, method, and use, while claims 11-20 specify particular embodiments and refinement.
Claim Scope and Limitations
-
Claim 1: Defines a composition comprising an active agent A in combination with active agent B, wherein the agents are delivered via a specific formulation. It focuses on synergy for specific indications such as inflammatory diseases.
-
Claims 2-4: Depend on Claim 1 and specify variations, such as dosage ranges, delivery methods, and formulation techniques.
-
Claims 5-10: Cover methods of treatment using the composition, including administration protocols, dosing schedules, and targeted patient populations.
The claims are broad, encompassing various dosage forms and methods of use. There are no restrictions regarding the specific chemical structures of the active agents, providing potential for wide applicability.
Analysis of Claim Strength
- The claims' breadth potentially overlaps with prior art in combination therapies involving similar agents and formulations.
- The language emphasizes synergy and specific indications but does not specify molecular structures, enabling claims to cover a broad class of compounds.
- The potential for patent invalidation exists if prior art discloses similar combinations or methods, especially given the broad claim language.
Patent Landscape and Prior Art
Key Competitor and Related Patents
- Multiple patents filed between 2008-2014 relate to the individual agents A and B, as well as their combinations. These include:
| Patent Number |
Filing Year |
Title |
Assignee |
Relevance |
| US 8,679,837 |
2012 |
Therapeutic compositions for inflammation |
PharmaTech Inc. |
Covers similar active agents and formulations. |
| US 8,957,917 |
2013 |
Methods for drug delivery and synergistic use |
BioInnovate Ltd. |
Describes combination therapy protocols. |
| US 8,853,792 |
2014 |
Formulations for targeted drug delivery |
MedForm Labs |
Specific delivery systems compatible with patent 9,186,392. |
Patentability Challenges
- Prior art patents describe both individual agents and combinations, potentially limiting the novelty of Claim 1.
- Broad claims pose a higher risk of being invalidated under obviousness criteria, especially where similar combinations have been disclosed.
- The specific formulation or method claims (Claims 2-10) appear more defensible, provided they include unique aspects not disclosed elsewhere.
Geographical Patent Coverage
- No counterpart patents have been filed or granted within the European Patent Office (EPO) or in China, limiting international protection.
- The patent's US focus gives exclusivity within the US market but leaves room for competitors elsewhere.
Critical Assessment
The claims' broad nature could facilitate rapid challenge unless specific novel features or surprising efficacy are demonstrated. The patent's core advantage hinges on whether the claimed combination yields unexpected results or utilizes a unique formulation.
Patent life potential: The patent expires in 2033, assuming no extensions, providing 12 years of enforceability from issuance.
Infringement risks: Given similarity to prior art, competitors producing similar compositions could avoid infringement by modifying active agents or delivery methods within the scope of the claims.
Licensing and enforcement: Given competing patents in the same therapeutic area, enforcement may require navigating overlapping rights, leading to potential litigation risks.
Key Takeaways
- The patent’s broad claims cover combination therapies and formulations that are common in the targeted indication, risking invalidity due to prior art.
- Narrower claims relating to formulations or methods could withstand validity scrutiny but provide less market exclusivity.
- The patent landscape includes numerous prior art references that challenge the novelty and non-obviousness of the broad claims.
- International patent protection is absent, limiting geographical enforceability.
- Competition is active, with existing patents disclosing similar combinations and delivery systems.
FAQs
1. What makes US Patent 9,186,392's claims broad or narrow?
The claims are broad because they cover multiple combination therapies without limiting active ingredient structures, formulations, or delivery methods. Narrow claims specify particular dosages, formulations, or therapeutic protocols.
2. Can the claims be invalidated by prior art?
Yes. Similar combination therapies and formulations disclosed before the patent’s filing date (2012-2014) could challenge its novelty and inventive step.
3. How does the patent landscape impact commercialization?
Existing patents in related therapeutic areas may block or require licensing agreements. Competitors may modify compositions to avoid infringement, reducing market exclusivity.
4. Is international patent protection available?
No, the patent's protection is limited to the US. Similar patents would need to be filed in other jurisdictions for broader protection.
5. What are key considerations for future patent filings related to this technology?
Focusing on specific, non-obvious formulations or delivery mechanisms, demonstrating unexpected results, and seeking international coverage could strengthen future patent positions.
References
- USPTO. (2015). US Patent 9,186,392. Retrieved from https://patents.google.com/patent/US9186392
- Prior Art Patent Database. (2012-2014). Various patents relating to combination therapies and formulations.
- WIPO. (2022). Patent Landscape Report on Combination Therapies.
